Difficult diagnosis of cardiac haemochromatosis: a case report

Vaida Sudmantaitė, Jelena Čelutkiene, Sigita Glaveckaite, and Rimgaudas Katkus

Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Santariskių 2, LT-08661 Vilnius, Lithuania

Received 14 July 2019; first decision 29 August 2019; accepted 16 January 2020; online publish-ahead-of-print 13 February 2020

Background
Primary iron overload cardiomyopathy is an important and potentially preventable cause of heart failure (HF), usually manifesting in the 4–5th decade of life. Patients may be asymptomatic early in the disease with hidden progression of cardiac dysfunction. The challenge of timely detection is an awareness of this systemic disorder and an adequate degree of clinical vigilance.

Case summary
A 48-year-old man was referred to the university clinic due to the episode of atrial fibrillation. The specific features of bronze skin and yellow eyes together with a combination of syndromes (cardiomyopathy, cirrhosis, ascites and portal hypertension, diabetes mellitus, and chronic kidney disease) stimulated the testing of iron metabolism markers, which were far above the normal range. Echocardiography and cardiac magnetic resonance (CMR) showed the dilatation of all cardiac cavities and biventricular systolic dysfunction. CMR T2* mapping was consistent with the diagnosis of myocardial and hepatic siderosis. Hereditary Type I haemochromatosis was confirmed by a genetic test. After 6 months of standard HF treatment, chelation therapy with deferiprone and regular phlebotomies imaging tests showed a reduction of ventricular and atrial volumes, an improvement in the cardiac systolic function and a decrease of iron accumulation.

Discussion
In this case, complicating syndromes were detected earlier than underlying disease of primary haemochromatosis. Cardiac haemochromatosis should be considered in any patient with unexplained HF, especially in the case of a positive family history, abnormal liver enzymes, endocrinopathies, or evidence of involvement of other organ systems. Screening for systemic iron overload with transferrin saturation and serum ferritin is the first step. Further non-invasive imaging tests should be done to confirm organ involvement.

Keywords
Case report • Haemochromatosis • Iron overload • Cardiac • Cardiomyopathy • Hereditary • Cirrhosis

Learning points
• Haemochromatosis is an important specific cause of heart failure, and it’s often asymptomatic until the middle age, at which point iron levels finally exceed the storage capacity of cells and tissue damage occurs.
• Physicians should remember the red flags of this disease: combination of bronze skin, diabetes, cirrhosis, arthritis, and cardiomyopathy.
• Cardiac magnetic resonance with measurement of T2* relaxation time is superior to other diagnostic modalities since it allows not only to detect but also to quantify myocardial iron overload.

* Corresponding author. Tel: +370 616 00180, Fax: +370 5 2501742, Email: jelena.celutkiene@santa.lt
Handling Editor: Pankaj Garg
Peer-reviewers: Magdy Abdelhamid, Luca Arcari, Suzan Hatipoglu, and Nisha Mistry
Compliance Editor: Rahul Mukherjee
Supplementary Material Editor: Peysh A. Patel
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
**Introduction**

Cardiac haemochromatosis is an important and potentially preventable cause of heart failure (HF). However, this condition is often diagnosed in the latter stages of the disease, when complications may have already developed. Iron deposition in the heart often causes arrhythmias and progressive systolic dysfunction. This usually manifests itself in the form of dilated cardiomyopathy with low left ventricular ejection fraction (LVEF), which can be reversible only if it is diagnosed and treated in its early stages. This unique genetic condition is often asymptomatic until the middle age, at which point iron levels finally exceed the storage capacity of cells and tissue is damaged, resulting in cirrhosis, hypogonadism, diabetes, arthropathy, cardiomyopathy, and skin pigmentation. In this case, we discuss the difficulties of differential diagnosis of cardiac haemochromatosis and the effect of specific and HF treatment.

**Timeline**

| Event                                | Details                                                                 |
|--------------------------------------|-------------------------------------------------------------------------|
| The start of the disease (2013)      | Typical symptoms and signs of heart failure (HF), biventricular dilative cardiomyopathy. |
| Clinical manifestation                | Cirrhosis (Child B class) with hepatosplenomegaly, ascites and portal hypertension, diabetes mellitus with diabetic foot, chronic kidney disease, and HF. |
| Clinical presentation (2017)          | Patient was referred to hospital due to the episode of atrial fibrillation. Objectively: bronze-shaded skin, telangiectasia on the shoulders, and slightly yellowish eyes. Electrocardiogram: atrial fibrillation, decreased voltage on the main limbs leads. Iron metabolism markers: serum ferritin, transferrin saturation, and iron level above the normal range. Echocardiography: the dilatation of all cardiac cavities and biventricular systolic dysfunction. CARDIAC MAGNETIC RESONANCE (CMR) was performed on a 1.5 T scanner (Siemens Avanto, Erlangen, Germany) with measurement of T2* relaxation time of the heart and liver, and LV function, volumes, and mass. The morphometric, functional and T2* relaxation values are presented in Table 2. The changes in LV systolic function and liver before and after treatment are illustrated in the Supplementary material online. Images S1a–c, S2a, S3a, and S4a, b. Cardiac magnetic resonance findings were consistent with the diagnosis of myocardial and hepatic siderosis. Hereditary or Type I haemochromatosis (HHC) was confirmed by a genetic test, showing the potential (>90%) homozygous genotype for the C282Y mutation of the HFE gene. During 2 weeks of hospitalization specific therapy with deferiprone and standard HF treatment was initiated, regular phlebotomies (removing about 500 mL of blood) were also scheduled. Medical treatment at different timepoints is presented in Table 3. Dietary advice included restrictions of iron intake (meaning to avoid red meat, crustaceans), as well as vitamin C and alcohol. The chelate, used for about 1 month, was discontinued due to limited availability and high cost in Lithuania. The improvement of iron metabolism markers was interpreted as a good response to regular phlebotomies, therefore, a multidisciplinary team decided to leave therapeutic phlebotomy (every 2 weeks) as a main treatment for haemochromatosis. |
| Confirmation                          | Genetic test confirmed hereditary type I haemochromatosis. |
| 6 months after treatment              | Cardiac magnetic resonance: the reduction of ventricular and atrial volumes, LVEF 52%, RVEF 50%, as well as positive dynamics of T2* relaxation times: 10.5 ms and 3.2 ms in the myocardium and liver, respectively. |

**Case presentation**

A 48-year-old-man was referred to the Vilnius University Hospital Santaros Klinikos due to atrial fibrillation with a rapid ventricular response, which was subsequently restored to sinus rhythm by using DC cardioversion. Of note, his electrocardiography (Figure 1) additionally showed decreased voltage in the limb leads and non-specific repolarization abnormalities. He presented with typical symptoms and objective signs of HF, and it was known from medical history that a previous echocardiography (done in 2013) had shown biventricular dilatation and impaired left ventricular (LV) function. Despite complaining of increasing weakness, fatigue, shortness of breath, and abdominal volume, the patient did not take any cardiac medication before index hospitalization. Transthoracic echocardiography confirmed significant biventricular dilatation and systolic dysfunction (LVEF 27%) with severe reduction of global and regional longitudinal strain (Figure 2). Ischaemic origin of HF was excluded during the initial workup by invasive angiography, family history was negative. Past medical history was significant for the following conditions: cirrhosis (Child B class) with hepatosplenomegaly, ascites and portal hypertension, diabetes mellitus with diabetic foot, and chronic kidney disease. Importantly, a subsequent more careful inspection revealed bronze-shaded skin, telangiectasia on the shoulders and abdomen, and slightly yellowish eyes. These special features combined with concomitant cirrhosis, diabetes, and cardiomyopathy stimulated the testing of iron metabolism markers. Laboratory tests’ results consistent with iron overload and their dynamic changes after treatment are presented in the Table 1.

In order to detect the iron accumulation in the heart cardiac magnetic resonance (CMR) was performed on a 1.5 T scanner (Siemens Avanto, Erlangen, Germany) with measurement of T2* relaxation time of the heart and liver, and LV function, volumes, and mass. The morphometric, functional and T2* relaxation values are presented in Table 2. The changes in LV systolic function and liver before and after treatment are illustrated in the Supplementary material online. Images S1a–c, S2a, S3a, and S4a, b. Cardiac magnetic resonance findings were consistent with the diagnosis of myocardial and hepatic siderosis.

Hereditary or Type I haemochromatosis (HHC) was confirmed by a genetic test, showing the potential (>90%) homozygous genotype for the C282Y mutation of the HFE gene. During 2 weeks of hospitalization specific therapy with deferiprone and standard HF treatment was initiated, regular phlebotomies (removing about 500 mL of blood) were also scheduled. Medical treatment at different timepoints is presented in Table 3. Dietary advice included restrictions of iron intake (meaning to avoid red meat, crustaceans), as well as vitamin C and alcohol. The chelate, used for about 1 month, was discontinued due to limited availability and high cost in Lithuania. The improvement of iron metabolism markers was interpreted as a good response to regular phlebotomies, therefore, a multidisciplinary team decided to leave therapeutic phlebotomy (every 2 weeks) as a main treatment for haemochromatosis.

**Discussion**

Cardiac haemochromatosis is the term used to describe the cardiac dysfunction that results from the accumulation of iron in the heart whether from primary or secondary HHC with a varying degree of cardiac involvement. The mutations leading to hereditary HHC are not rare, especially among white populations. In Lithuania, the
The reported prevalence of C282Y mutation in the haemochromatosis (HFE) gene on chromosome 6 is 2.6% which is similar to the other Central and Eastern European countries with population of Slavic origin.\(^1\) Not all patients that are homozygous for C282Y or compound heterozygous (C282Y/H63D) develop iron overload.\(^2\) The factors affecting penetrance are sex, age, physiological and pathological blood loss, blood donation, dietary intake of iron, alcohol, hepatitis C and B, obesity, and the use of dietary supplements (iron and vitamin C). Additional mechanisms associated with HFE gene mutation, such as exacerbation of coronary artery disease, direct causation of dilative cardiomyopathy, or autoimmune processes, have been discussed.\(^2\)

Our case demonstrates the complexity of storage disease diagnosis. The clinical syndromes, complicating the main underlying disease, were determined first, without a recognition of particular aetiology of those. However, a combination of clinical manifestations such as chronic fatigue, lethargy, bronze skin, arthritis, cardiomyopathy, diabetes, and cirrhosis should serve as red flags and lead the scrupulous clinician to the suspicion of iron metabolism disorder (Figure 3).

Cardiac magnetic resonance with measurement of T2* relaxation time is superior to other diagnostic modalities since not only it allows not only to detect but also to quantify myocardial iron overload.\(^3\) The time constant of decay for relaxation time is inversely proportional to the iron content in the tissue: the higher iron content, the shorter T2*.\(^4\) Diastolic cardiac dysfunction secondary to restrictive physiology may be seen early in the disease, while later dilated cardiomyopathy with LV systolic dysfunction may prevail. Newer modalities such as strain imaging hold promise for earlier detection of cardiac involvement.\(^5,6\)

The diagnostic pathway of our patient is presented in Figure 3. The combination of magnetic resonance imaging of the heart and liver with the result of genetic testing made a liver or cardiac biopsy unnecessary in this case.\(^7\) The management of iron overload with proper iron chelation therapy and therapeutic phlebotomy guided by CMR T2* relaxometry is the key to haemochromatosis treatment, in
### Table 1  Laboratory tests results at baseline and 6 months after treatment

| Parameter                | Measurement units | Baseline | 6 months after treatment | Normal range |
|--------------------------|-------------------|----------|--------------------------|--------------|
| Ferritin                 | μg/L              | 2742.8   | 185.5                    | 20–300       |
| Transferrin saturation   | %                 | 94.9     | NA                       | 2–3.6        |
| Iron                     | μmol/L            | 39.1     | NA                       | 9.5–29.9     |
| BNP                      | ng/L              | 981.2    | NA                       | <100         |
| Troponin I               | ng/L              | 85       | 50.3                     | <34.2        |
| Serum creatinine         | μmol/L            | 175      | 62                       | 62–115       |
| Albumin                  | g/L               | 34.6     | 41.9                     | 35–52        |
| ALP                      | U/L               | 147      | 200                      | 40–150       |
| AST                      | U/L               | 152      | 69                       | ≤40          |
| ALT                      | U/L               | 84       | 50                       | ≤40          |
| Total bilirubin          | μmol/L            | 36       | 18                       | <21          |
| Direct bilirubin         | μmol/L            | 15       | 9.4                      | <5.3         |
| Indirect bilirubin       | μmol/L            | 21       | 9.0                      | <15.7        |
| Serum glucose            | mmol/L            | 7.15     | 9.1                      | 4.2–6.1      |
| Hgb                      | g/L               | 148      | 130                      | 128–160      |
| Hct                      | L/L               | 0.423    | 0.391                    | 0.4–0.52     |
| CRP                      | mg/L              | 12.6     | 1.2                      | ≤5           |

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BNP, brain natriuretic peptide; CRP, C-reactive protein; Hct, haematocrit; Hgb, haemoglobin.

### Table 2  Dynamics of cardiac structure and function assessed by TTE and CMR at baseline and 6 months after treatment

| Transthoracic echocardiography | Baseline | 6 months after treatment | Normal range |
|-------------------------------|----------|--------------------------|--------------|
| LVEF (%)                      | 27       | 50                       | ≥55          |
| TAPSE (cm)                    | 1.3      | 1.8                      | ≥1.7         |
| IVC_{exp} (cm)                | 3        | 2                        | ≤2.1         |
| IVC_{ins} (cm)                | 2.8      | —                        | ≤1.7         |
| IVC_{collapse} (%)           | 6.6      | —                        | ≥50          |

| Cardiac magnetic resonance    | Baseline | 6 months after treatment | Normal range |
|-------------------------------|----------|--------------------------|--------------|
| LVDD (cm)                     | 6.4      | 5.7                      | ≤5.9         |
| LVPWDD (mm)                   | 10       | 8                        | ≤10          |
| IVSDD (mm)                    | 11       | 11                       | ≤10          |
| LVEDVI (mL/m²)                | 123      | 81                       | <92          |
| LVESVI (mL/m²)                | 88       | 39                       | <30          |
| LVEF (%)                      | 28       | 52                       | ≥55          |
| RVESVI (mL/m²)                | 95       | 41                       | <43          |
| RVF (%)                       | 26       | 50                       | ≥47          |
| CI (l/min/m²)                 | 2.5      | 3.2                      | ≥2.82        |
| LA area 4 ch (cm²)            | 37       | 29                       | ≤29          |

**CMR T2\* relaxation time**


| Septal myocardium (ms)       | 8.8      | 10.5                     | ≥20          |
| Liver tissue (ms)            | 2.5      | 3.2                      | >6.3         |

Cl, cardiac index; IVC_{exp}, inferior vena cava at expiration; IVC_{ins}, inferior vena cava at inspiration; IVC_{coll}, inferior vena cava at collapse; IVSDD, intraventricular septum diastolic diameter; LA, left atrium; LVDD, left ventricular diastolic diameter; LVEDVI, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end-systolic volume index; LVPWDD, left ventricular posterior wall diastolic diameter; RVESVI, right ventricular end-diastolic volume index; RVF, right ventricular ejection fraction; RVESVI, right ventricular end-systolic volume index; TAPSE, tricuspid annular plane systolic excursion.

\*Standard deviation of T2 values in scan and rescan is <0.4 ms.
addition to other diseases-specific modalities and the conventional HF therapy.\(^8\) Close family members of newly diagnosed patients should be screened for an asymptomatic disease.

The treatment decisions were influenced by the limited availability and high cost of chelates in Lithuanian market, with deferiprone accessible only. According to the recommendations,\(^7–9\) phlebotomies are the treatment of choice in non-anaemic patients, with ferritin level \(>300\, \mu g/L\) in men; with haemoglobin and haematocrit levels ranging within \(120–130\, g/L\) and \(0.38–0.41\), respectively, phlebotomy was considered as adequate therapy for our patient, giving a positive response.

A marked and clinically significant improvement in LVEF was observed in our case; first of all, it may be attributed to the well-known effect of anti-remodelling therapy of angiotensin-converting enzymes inhibitor, beta-blocker, and mineralocorticoid receptor antagonist,\(^10\) which was newly started during index hospitalization. Second, partially effect may be associated with a reduction of iron accumulation, which similarly was reported in haemochromatosis cases by other authors.\(^11,12\) The difference between follow-up and baseline values of LVEF far exceeds the established variability of this parameter.\(^13\) However, the increase of T2\(^*\) relaxation times in the heart and liver was relatively low compared with other cases reported in the literature\(^14,15\); it may be explained by the lack of chelating therapy for our patient.

**Conclusion**

Hereditary or Type I haemochromatosis is an important specific cause of HF, usually manifesting in the 4–5th decade. Timely detection of this systemic disorder could prevent multiple organ damage. Physicians should remember the red flags of this disease: combination of bronze skin, diabetes, cirrhosis, arthritis, and cardiomyopathy. Biochemical indicators and T2\(^*\) relaxation time on CMR provide not only diagnostic value but also in addition help to quantify the treatment effect. Specific chelation, regular phlebotomies, and standard therapy are the cornerstones of successful treatment.

---

**Table 3  Medical treatment at different timepoints**

| Medication   | Daily dose | First hospitalization | After 1 month   | After 6 months |
|--------------|------------|-----------------------|-----------------|----------------|
| Insulin      | 54–56 Units| 38–42 Units           | 24–28 Units     |
| Furosemid    | 120 mg     | 160 mg                | 80–120 mg       |
| Torasemid    | 50 mg      | 50 mg                 | 25 mg           |
| Spironolacton| 200 mg     | 50 mg                 | 100 mg          |
| Carvedilol   | 18.75 mg   | 18.75 mg              | 18.75 mg        |
| Perindopril  | 2.5 mg     | 2.5 mg                | 2.5 mg          |
| Rivaroxaban  | —          | 20 mg                 | 20 mg           |
| Deferiprone  | 3000 mg    | 6000 mg               | —\(^a\)         |
| Phlebotomy   | Weekly (500 mL) | Weekly (500 mL) | Every 10–14 days (500 mL) |

\(^a\)Interrupted due to limited availability and high cost of deferiprone.
HF treatment may demonstrate significant benefit even in the advanced stage.

**Lead author biography**

Vaida Sudmantaitė, 5th-year medical student, is studying at the Faculty of Medicine in Vilnius University, Lithuania. Sudmantaitė is interested in cardiology since the first contact with human anatomy. She is engaged in scientific activities of cardiology and also volunteered at cardiology department.

**Supplementary material**

Supplementary material is available at *European Heart Journal - Case Reports* online.

**Slide sets:** A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

**Consent:** The author/s confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidance.

**Conflict of interest:** none declared.

**References**

1. Kucinskas L, Juzenas S, Juzenaitė J, Cedaviciute R, Vitkauskienė A, Kalibatė V, Kondrackiene J, Kupcis K. Prevalence of C282Y, H63D, and S65C mutations in hereditary HFE-hemochromatosis gene in Lithuanian population. *Ann Hematol* 2012;91:491–495.
2. Carpenter JP, Grasso AE, Porter JB, Shah F, Dooley J, Pennell DJ. On myocardial siderosis and left ventricular dysfunction in hemochromatosis. *J Cardiovasc Magn Reson* 2013;15:24.
3. Lota AS, Gatehouse PD, Mohiuddin R. T2 mapping and T2* imaging in heart failure. *Heart Fail Rev* 2017;22:431–440.
4. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennell DJ. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. *Circulation* 2009;120:1961–1968.
5. Cascades A, Sanchez-Vega B, Navarro N, Pastor-Quirante F, Corral J, Vicente V, de la Pea FA. Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation. *Int J Cardiol* 2012;154:282–286.
6. Galiati V, Hankirishnan P, Palaniswaamy C, Aranow WS, Jain D, Frishman WH. Cardiac involvement in hemochromatosis. *Cardiol Rev* 2014;22:56–68.
7. Bacon BR, Adams PC, Kowdle KY, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. *Hepatology* 2011;54:328–343.
8. Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. *Circulation* 2011;124:2253–2263.
9. Aranow W. Management of cardiac hemochromatosis. *Arch Med Sci* 2018;14:560–568.
10. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, Jackson R, Rahmiva T, Wage R, Smith G, Vennier L, Tayal U, Auger D, Midwinter W, Whittin N, Rajani N, Dangoo JN, Pantazis A, Cook SA, Ware JS, Baksy AJ, Pennell DJ, Rosen SD, Cowie MR, Cleland JGF. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. *Circulation* 2019;139:61–73.
11. Huijskes RVHP, Hoogenberg K, Wiesfeld ACP, Pijl MEJ, van Gelder IC. Phlebotomies as a treatment of serious heart failure due to haemochromatosis: a case report. *Neth Heart J* 2009;17:438–441.
12. Tauchenova L, Krizova B, Kubanek M, Frankova S, Melenovsky V, Tintera J. Successful treatment of iron-overload cardiomyopathy in hereditary hemochromatosis with deferoxamine and deferiprone: a case report. *Can J Cardiol* 2016;32:1574.e1–1574.e3.
13. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. *J Am Coll Cardiol* 2013;61:77–84.
14. Hilbert T, Sumpf TJ, Weiland E, Frahm J, Thiran JP, Meuli R, Kober T, Krueger G. Accelerated T2 mapping combining parallel MRI and model-based reconstruction: GRAPPA TIN J *Magn Reson Imaging* 2018;48:359–368.
15. Alam MH, He T, Auger D, Smith GC, Drivas P, Wage R, Isga C, Symmonds K, Grosser A, Spottswoode BS, Anderson L, Firmin D, Pennell DJ. Validation of T2* in-line analysis for tissue iron quantification at 1.5 T. *J Cardiovasc Magn Reson* 2016;18:23.